Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-02-20
2007-02-20
Le, Long V. (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007920, C435S007940, C435S810000, C435S007200, C436S514000, C436S536000, C436S086000, C436S063000, C436S151000
Reexamination Certificate
active
09993289
ABSTRACT:
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.
REFERENCES:
patent: 5062935 (1991-11-01), Schlag et al.
patent: 6020208 (2000-02-01), Hutchens et al.
patent: 6225047 (2001-05-01), Hutchens
patent: 1 070 962 (2001-01-01), None
patent: WO 90/14148 (1990-11-01), None
patent: WO 93/24834 (1993-12-01), None
patent: WO 95/25281 (1995-09-01), None
patent: WO 98/07036 (1998-02-01), None
patent: WO 98/22617 (1998-05-01), None
patent: WO 01/75454 (2001-10-01), None
Bernard et al. Human Cellular Fibroection Biochemistry (1985) 24:2698-2704.
Zhang et al. Neurobiology of Aging (2005), vol. 26, pp. 207-227.
Takahashi et al., “Rapid and Sensitive Immunoassay for the Measurement of Serum S100β Using Isoform-specific Monoclonal Antibody”, Clinical Chemistry 45, No. 8, (1999) pp. 1307-1311.
Richter et al., “Composition of the peptide fraction in human blood plasma: database of circulating human peptides”, Journal of Chromatography B; 726 (1999) pp. 25-35.
Van Gool, et al., “Appearance of localized immunoreactivity for the α4 integrin subunit and for fibronectin in brains from Alzheimer's, Lewy bidy dementia patients and aged controls”, Neuroscience Letters (1994) vol. 170, No. 1, pp. 71-73.
Howard, et al., “Antibodies to fibronectin bind to plaques and other structures in Alzheimer's disease and control brain”, Neuroscience Letters (1990) vol. 118, No. 1, pp. 71-76.
Kashiwagi, et al., “Sequential Changes in Plasma Fibronectin in Patients with Subarachnoid Hemorrhage”, Neurol Med Chir (1993) vol. 33, No. 4, pp. 225-228.
Rattan, et al., “Unchanged concentration of plasma fibronectin in Alzheimer's disease”, Journal of Clinical Pathology (1988) vol. 41, No. 4, p. 476.
Sickmann, et al., “Towards a high resolution separation of human cerebrospinal fluid”, Journal of Chromatography (2002) vol. 771, No. 1-2, pp. 167-196.
Schrader, et al., “Peptidomics technolgies for human body fluids”, Trends in Biotechnology (2001) vol. 19, No. 10, pp. 555-560.
Retta, et al., “Purification of Fibronectin from Human Plasma”, Methods in Molecular Biology (1999) vol. 96, pp. 119-130.
Kiernan, et al., “Detection of novel truncated forms of human serum amyloid A protein in human plasma”, FEBS Letters (2003) vol. 537, No. 1-3, pp. 166-170.
Jackowski George
Marshall John
Cheu Jacob
Le Long V.
McHale & Slavin P.A.
Nanogen Inc.
LandOfFree
Fibronectin precursor biopolymer markers indicative of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fibronectin precursor biopolymer markers indicative of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fibronectin precursor biopolymer markers indicative of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3845848